McDermott Wins Reversal on Galderma Anti-Acne Patent
Galderma's monopoly on its brand-name acne treatment Differin Gel 0.3% went up in smoke on Wednesday, when the generic drug company Tolmar Inc. and its lawyers at McDermott Will persuaded the Federal Circuit to invalidate Galderma's patents.
This premium content is reserved for American Lawyer subscribers.
Continue reading by getting started with a subscription.
Already a subscriber? Log in now